Zepbound (Tirzepatide) Nausea Severity Grading Rubric

What can a Zepbound nausea grade actually rest on?

The label reports nausea as one all-grade rate for each dose, and reports severe gastrointestinal adverse reactions as a separate combined category rather than publishing a severe-nausea rate of its own [1]. It does not grade nausea by food or fluid intake, and it gives no patient counts for any intake-based category. Eating, drinking and vomiting are still useful plain ways to describe how a person is doing day to day, which is how the tiers below are set out.

A three-tier way to describe symptom severity

Tier 1: nausea with intake maintained

Features: nausea reported, no vomiting, eating and drinking continuing.

Where these symptoms sit in the trial data: nausea was the most frequently reported adverse reaction at every Zepbound dose in the pooled weight-management trials (25%, 29% and 28% at 5, 10 and 15 mg versus 8% on placebo), while vomiting was 8%, 11% and 13% versus 2% and discontinuation for gastrointestinal reasons was 1.9%, 3.3% and 4.3% versus 0.5% [1].

Tier 2: nausea that limits intake, or vomiting

Features: meals missed, vomiting, reduced fluid intake.

What the label flags here: postmarketing acute kidney injury, in some cases requiring hemodialysis, with the majority of reported events in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].

Tier 3: persistent vomiting or inability to keep fluids down

Features: persistent vomiting, or inability to keep fluids down.

The label reports severe gastrointestinal adverse reactions across several types of symptoms: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg versus 1% on placebo, with similar rates in the OSA trials [1]. Zepbound is not recommended in patients with severe gastroparesis [1].

Persistent or severe abdominal pain, sometimes radiating to the back, is a separate warning sign for possible pancreatitis, with or without nausea or vomiting. Acute pancreatitis has been observed with GLP-1 receptor agonists and with Zepbound, and the label says to discontinue Zepbound if pancreatitis is suspected [1].

Gallbladder disease is a separate label warning, not a nausea grade: cholecystitis was reported in 0.7% of Zepbound-treated patients versus 0.2% on placebo, and acute gallbladder events were associated with weight reduction [1].

How common is nausea at each Zepbound dose?

The label's figures come from a pool of two placebo-controlled weight-management trials in adults with obesity or overweight, with or without type 2 diabetes, lasting up to 72 weeks: 958 patients on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1].

• Nausea: 8% placebo, 25% at 5 mg, 29% at 10 mg, 28% at 15 mg [1]
• Diarrhea: 8%, 19%, 21%, 23% [1]
• Vomiting: 2%, 8%, 11%, 13% [1]
• Constipation: 5%, 17%, 14%, 11% [1]
• Abdominal pain: 5%, 9%, 9%, 10% [1]
• Dyspepsia: 4%, 9%, 9%, 10% [1]

Any gastrointestinal adverse reaction occurred in 56% of patients at every Zepbound dose versus 30% on placebo, and permanent discontinuation for any adverse reaction was 4.8% at 5 mg, 6.3% at 10 mg and 6.7% at 15 mg versus 3.4% on placebo; the label says the majority of those who stopped did so in the first few months because of gastrointestinal reactions [1]. The dose relationship is not a straight line: nausea was slightly more frequent at 10 mg than at 15 mg [1].

When in treatment does nausea appear?

The label states that the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. It also notes that tirzepatide delays gastric emptying, that the delay is largest after the first dose, and that it diminishes over time [1].

What the label says about dose steps and tolerability

The Zepbound label specifies 2.5 mg weekly for initiation and 5 mg weekly after four weeks, with further 2.5 mg increments after at least 4 weeks on the current dose; it says to consider tolerability when selecting a maintenance dose [1]. The 2.5 mg dose is for initiation only and is not approved as a maintenance dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg weekly, and 10 or 15 mg weekly for obstructive sleep apnea, with a maximum of 15 mg [1]. The label says the escalation schedule is followed to reduce the risk of gastrointestinal adverse reactions, and that if a maintenance dose is not tolerated, a lower maintenance dose may be considered [1].

Zepbound nausea compared with semaglutide nausea

In SURPASS-2, a 40-week trial of 1,879 adults with type 2 diabetes on metformin, nausea was reported by 17% to 22% of patients on tirzepatide 5, 10 or 15 mg versus 18% on semaglutide 1 mg, and vomiting by 6% to 10% versus 8% [2]. In SURMOUNT-5, a 72-week head-to-head trial of 751 adults with obesity and no diabetes, gastrointestinal events were the most common adverse events in both the tirzepatide and semaglutide groups and most were mild to moderate in severity [3].